title: Additional results for 'Sequential design approaches for bioequivalence studies with crossover designs'.
abstract: In 2008, this group published a paper on approaches for two-stage crossover bioequivalence (BE) studies that allowed for the reestimation of the second-stage sample size based on the variance estimated from the first-stage results. The sequential methods considered used an assumed GMR of 0.95 as part of the method for determining power and sample size. This note adds results for an assumed GMR = 0.90. Two of the methods recommended for GMR = 0.95 in the earlier paper have some unacceptable increases in Type I error rate when the GMR is changed to 0.90. If a sponsor wants to assume 0.90 for the GMR, Method D is recommended. Copyright © 2011 John Wiley & Sons, Ltd.
authors.affiliation: GlaxoSmithKline, Inc., King of Prussia, PA, USA.
authors.forename: Timothy H
authors.initials: TH
authors.lastname: Montague
authors.forename: Diane
authors.initials: D
authors.lastname: Potvin
authors.forename: Charles E
authors.initials: CE
authors.lastname: Diliberti
authors.forename: Walter W
authors.initials: WW
authors.lastname: Hauck
authors.forename: Alan F
authors.initials: AF
authors.lastname: Parr
authors.forename: Donald J
authors.initials: DJ
authors.lastname: Schuirmann
mesh_terms: D018592:Cross-Over Studies; D006801:Humans; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D012107:Research Design; D013810:Therapeutic Equivalency
chemical_list: D004364:Pharmaceutical Preparations